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Summary  
Adrenocortical carcinoma patient prognosis is extremely variable and poorly predictable. The 
newly introduced Helsinki Score is the first so far proposed diagnostic and prognostic system based 
on the combined evaluation of morphological (mitoses and necrosis) and immunohistochemical 
(Ki-67) parameters. The aim of the study was to validate the prognostic role of the Helsinki Score 
for adrenocortical carcinoma characterization. Thus, 225 adrenocortical carcinomas were 
reclassified using the Weiss Score and the Helsinki Score (3× mitotic count + 5× necrosis + Ki-67 
index). At univariate analysis, statistically significant prognostic values were observed at the log-
rank test for mitotic count (cut-off values: <6 and ≥55; P < .0001), Ki-67 (cut-off values: <20 and 
≥50; P < .0001), Weiss Score (cut-off values: <5 and ≥8; P < .0001), Helsinki Score (cut-off values: 
<13 and ≥19; P < .0001), histological variant (conventional vs oncocytic; P = .009), necrosis (P 
= .001) and stage (P = .005). Cox multivariate analysis using a backward stepwise selection method 
retained only Helsinki Score and Weiss Score as predictors of poor prognosis (P < .0001 and P 
= .0005, respectively). Helsinki Score (with a threshold of 28.5 points; AUC = 0.729, 95% 
confidence interval [CI] = 0.66-0.79) and Ki-67 (with a threshold of 20.5%; AUC = 0.727, 95% CI 
= 0.66-0.79) showed the best and equivalent areas under the curve (AUC) predicting disease-related 
deaths determined using receiver-operating characteristic statistics. In conclusion, the Helsinki 
Score is a valuable system to predict prognosis in adrenocortical carcinoma, outperforming the 
currently established prognostic parameters. 
 
Keywords: Adrenocortical carcinoma; Helsinki Score; Ki-67; Prognosis 
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1. Introduction 
Adrenocortical carcinoma (ACC) has a heterogeneous morphology in its classical form and 
also includes several histological variants (oncocytic, myxoid and sarcomatoid). In addition, the 
prognosis of ACC patients is extremely variable and poorly predictable, with cases following a 
rapidly aggressive course along with tumors having an indolent clinical outcome. In the last 25 
years, the differential diagnosis between adrenocortical adenoma and carcinoma was defined using 
different scoring systems, such as the Weiss Score [1,2] or the Van Slooten Index [3], or 
algorithmic approaches, such as the mitosis method [4] or the Reticulin Algorithm [5,6]. Currently, 
the Weiss Score is still the most widely employed for diagnostic purposes, but it also possesses a 
prognostic value, at least at univariate survival analysis, high Weiss Score values being associated 
with a poor prognosis [7,8].  
Recently, a new score, the “Helsinki Score”, based on the combined evaluation of 
morphological parameters (presence of necrosis and a mitotic count >5 per 50 high-power fields) 
and Ki-67 proliferation index, was demonstrated to accurately predict the metastatic potential of 
adrenocortical carcinomas [9]. A cut-off value of 8.5 points was able to identify metastatic ACC 
with an extremely high sensitivity and specificity. In addition, a prognostic role was also identified 
with two groups of malignant neoplasms having different scores and different survival (score 8.5-17 
vs >17). The original study included a limited cohort of ACC, as among the 177 adrenocortical 
tumors analyzed, only 30 had a Weiss Score ≥3, 15 of which (50%) had a Helsinki Score >8.5. In 
addition, the applicability of the Helsinki Score was not mentioned for ACC morphological variants. 
These include the oncocytic variant, for which the Weiss Score is not applicable and the specific 
Lin-Weiss-Bisceglia system is generally used, being based on partially different parameters [10]. 
Based on the aforementioned, a study was designed on a large series of 225 ACC from two 
institutions to assess the prognostic role of the Helsinki Score both in conventional and special 
variants of ACC. 
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2. Materials and methods 
2.1. Case collection 
We retrieved 225 adrenocortical tumors having a Weiss Score ≥3 [1] from the pathology 
files of two Italian institutions between January 2004 and December 2015, namely the University of 
Turin at San Luigi Hospital (205 cases) and the University of Padua (20 cases). The majority of 
these patients were treated at San Luigi Hospital in Orbassano-Turin, which serves as one of the 
referral centers for ACC in Italy. The study received ethical approval from the local Review Board 
of San Luigi Hospital. The clinical and pathological features of the whole series are summarized in 
Table 1. 
 
2.2. Case classification  
All available hematoxylin and eosin–stained slides were reviewed by two of us (E.D. and 
M.V.) having a specific interest in endocrine pathology and classified according to the appropriate 
diagnostic systems, ie, Weiss Score [1] and Revised Weiss Score [2] for conventional ACC, Lin-
Weiss-Bisceglia System [10] for pure oncocytic adrenocortical tumors and Wienecke classification 
[11] for pediatric tumors. In addition, the Helsinki Score [9] was generated as follows: 3 points for a 
mitotic count >5/50 high-power fields + 5 points in the presence of necrosis + the absolute value of 
Ki-67 proliferation index (Fig. 1).  
 
2.3. Immunohistochemistry  
From a representative paraffin block for each case, 5-μm-thick serial paraffin sections were 
processed by means of immunohistochemistry using an antibody against Ki-67 (clone MIB-1, 
diluted 1:150; Dako-Agilent, Glostrup, Denmark). A biotin-free, dextran chain–based detection 
system (EnVysion, Dako) and diaminobenzidine as the chromogen were used according to a 
standard protocol. Ki-67 proliferation index was determined by counting 1000 cells in hot spots and 
calculated as the percentage of positive neoplastic nuclei. The Ki-67 values of 51 cases belonging to 
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this data set have already been reported [12]. 
 
2.4. Statistical analysis  
Nonparametric tests (Wilcoxon rank-sum and Kruskal-Wallis rank-sum) were used to 
analyze differences between various conditions. Fisher exact test analyzed differences in categorical 
variables. Spearman ρ coefficient was calculated to assess correlations among various parameters. 
Survival curves were estimated with the Kaplan-Meier method and were compared with the log-
rank test. Cox proportional hazards regression (HR) models were used both to estimate the HRs and 
for multivariate survival analyses. The ROC curves and the area under the ROC curve (AUC) were 
used to assess scores’ ability to differentiate between “status” (alive vs dead). Two cut-off points for 
mitotic count, Ki-67 proliferation index, Weiss Score and Helsinki Score, which divided cases into 
three prognostically different groups, were selected both on the basis of the highest statistical 
significance in the log-rank test and with maximizing the Youden index in the context of the ROC 
surface. The volume under ROC surface (VUS) was taken as the global measure summarizing the 
test discrimination power. A significance level of P < .05 was used. 
 
3. Results 
All scoring systems were well correlated (Table 2). At univariate analysis of overall survival 
with the Cox model, high values of mitotic count, Ki-67 proliferation index, Weiss Score (both its 
original and revised form) and Helsinki Score, all used as numerical scores, were strongly 
associated with a poor prognosis. In addition, other clinical (ENSAT stage and hormonal secretion) 
and pathological parameters (size of the tumor, presence of necrosis and conventional/myxoid 
variant) were associated with a shorter overall survival. Cox multivariate analysis using a backward 
stepwise selection method revealed Helsinki Score and Weiss Score to be the sole predictors of 
poor prognosis (Table 3).  
Specific cut-off points for mitotic count, Ki-67 proliferation index, Weiss Score and 
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Helsinki Score, which divided cases into three distinct prognostically different groups, were 
selected on the basis of the highest statistical significance on the log-rank test. The optimal cut-offs 
were <6 and ≥55 for mitotic count, <20 and ≥50 for Ki-67 proliferation index, <5 and ≥8 for Weiss 
Score and, finally, <13 and ≥19 for Helsinki Score (Fig. 2). Concerning the Helsinki Score, the cut-
offs proposed by Pennanen et al [9] (<8.5 and >17) were also used, however, resulting in a lower 
performance in term of prognostic stratification. 
To further determine the prognostic power of the numerical variables to assess scores’ 
ability to differentiate between “status” (ie, different scores and mitotic/proliferation indexes), ROC 
curves were plotted and the AUC calculated. The best and equivalent AUCs were found for 
Helsinki Score (with a threshold of 28.5 points; AUC=0.729, 95% confidence interval [CI] = 0.66-
0.79) and Ki-67 (with a threshold of 20.5%; AUC=0.727, 95% CI = 0.66-0.79) compared to mitotic 
count (with a threshold of 15 mitoses/50 HPF; AUC=0.673, 95% CI = 0.603-0.74), Weiss Score 
Revised (with a threshold of 5; AUC=0.646, 95% CI = 0.573-0.646) and Weiss Score (with a 
threshold of 7; AUC=0.624, 95% CI = 0.55-0.7) (Fig. 3).  
In the present study, purely oncocytic tumors and myxoid neoplasms with Weiss score ≥3 
accounted for 10.0% (24/225) and 7.5% (17/225) of the whole series, respectively. After applying 
the LWB classification for oncocytic tumors, 1 oncocytic case was reclassified as benign, 5 as 
“uncertain malignant potential” (UMP), while the remaining 18 were confirmed as malignant. The 
benign case and all 5 UMP cases had a Helsinki Score ranging from 1 to 6, except for one UMP 
case with a score of 25. Conversely, malignant cases (according to LWB classification) had a 
Helsinki Score ranging from 3 to 79. When the above proposed Helsinki Score cut-offs (<13 vs ≥19) 
were applied, 15 cases (12 alive with no evidence of disease and 3 alive with disease) were 
allocated in the group with better prognosis; no cases had a score between 13 and 19, while the 
remaining 9 cases (5 alive with no evidence, 2 alive with disease and 2 died of disease) belonged to 
the group associated with a worse prognosis (Fig. 4A). Consistently, patients with Helsinki Score 
≥19 had decreased survival compared with those with Helsinki Score <13 (log-rank test, P = .015, 
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mean survival of 32 months and 74 months for Helsinki Score ≥19 and <13, respectively).  
Concerning myxoid tumors, 3 cases (2 without evidence of disease and 1 alive with disease) 
had a Helsinki Score lower than 13, while 14 (1 without evidence of disease, 8 alive with disease 
and 6 died of disease) had a Helsinki Score higher than 19 (Fig. 4B). Myxoid cases were too few to 
perform a further specific survival analysis. 
 
4. Discussion 
In the present study, the Helsinki Score emerged as the most relevant system with an impact 
on prognosis, outperforming the most established prognostic parameters such as clinical stage, 
mitotic index and Ki-67 proliferation index. In addition, it turned out to be applicable to both 
conventional and oncocytic variant of ACC. 
Since its introduction in 1984 [1], the Weiss Score has obtained the widest acceptance by 
practicing pathologists worldwide to determine the malignant potential among adrenocortical 
tumors. Consistently, it has been integrated in several molecular studies [13-16]. Beyond its 
diagnostic role, the Weiss Score also possesses prognostic significance [7], because high Weiss 
Score tumors generally display an aggressive clinical behavior [8], although this finding was not 
confirmed in other papers [17,18]. The newly introduced Helsinki Score [9] is the first so far 
proposed system based on the combined evaluation of morphological (mitoses and necrosis) and 
immunohistochemical (Ki-67) parameters. The morphological criteria are among the most 
reproducible [19] and prognostically relevant [5,20] among those included in the Weiss Score. As a 
matter of fact, in 1989 Dr Weiss himself proposed a mitotic count–based, two-tier grading system, 
distinguishing low-grade (<20/50 HPF) from high-grade ACC (>20/50 HPF) [20]. Concerning Ki-
67 proliferation index, several groups proved its superiority to mitotic count to prognosticate ACC, 
although the optimal cut-offs are still to be identified among those so far proposed by our group [12] 
(<20%, 20%-50% and >50%) and by Beuschlein et al [8] (<10%, 10%-20%). In addition, a recent 
international reproducibility study involving 14 endocrine pathologists [21] revealed that Ki-67 
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assessment has a great interobserver variation, which imposes particular limitations to its clinical 
utility, especially around clinically relevant cut-offs.  
In the present large series of ACC from two institutions, a statistically significant prognostic 
value at univariate analysis was observed only for those two morphological parameters of the Weiss 
Score included in the Helsinki Score (necrosis and mitotic count), for Ki-67 proliferation index, for 
the Weiss Score and the Helsinki Score itself. Interestingly, at Cox multivariate analysis, only the 
Weiss Score and the Helsinki Score, and not mitotic count nor Ki-67 index alone, were confirmed 
as predictors of poor prognosis (P < .0001 and P = .0005, respectively). However, ROC statistics 
revealed that the best and equivalent AUC to predict the occurrence of disease-related deaths were 
those of Helsinki Score (with a threshold of 28.5 points) and Ki-67 (with a threshold of 20.5%). 
Such a preponderance of the Helsinki Score above the other established prognostic parameters can 
be easily explained observing that the Helsinki Score is a unique tool that combines the most 
prognostically relevant morphological parameters of the Weiss Score and Ki-67 proliferation index. 
As our series included both conventional and morphological variants of ACC, we could also 
verify the prognostic value of the Helsinki Score in oncocytic and myxoid ACC cases, although the 
number of cases in the latter group was not enough for statistical analysis of survival. In fact, 
applying the newly proposed cut-offs (<13 vs ≥19), the Helsinki Score demonstrated a worse 
prognosis for oncocytic neoplasms having a score ≥19 with a 66% probability of correctly 
classifying the aggressive cases and to predict the occurrence of disease-related deaths. Regarding 
the myxoid variant of ACC, whose malignancy risk is potentially underestimated by the Weiss 
Score, the probability of correctly classifying aggressive cases with the Helsinki Score was even 
higher (88%). 
In conclusion, the Helsinki Score is a valuable system to predict prognosis in ACC, 
outperforming in our series the currently established prognostic parameters.  
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FIGURE LEGENDS 
 
Fig. 1 Representative example of the Helsinki Score application. This case had 25 mitoses/50 HPF 
(A), diffuse areas of necrosis (B) and a Ki-67 proliferation index of 30%. Consistently the Helsinki 
Score was 38 (3 points for a mitotic count + 5 points in the presence of necrosis + 30 of Ki-67 
proliferation index) (A and B, hematoxylin and eosin, original magnification ×400; C, 
immunoperoxidase, ×400).  
. 
 
Fig. 2 Distinct prognostically different groups based on specific cut-off points for mitotic count (A), 
Ki-67 proliferation index (B), Weiss Score (C) and Helsinki Score (D). 
 
Fig. 3 ROC curves determining the prognostic power of the numerical variables. The best and 
equivalent AUCs were found for Helsinki Score (A, threshold= 28,5 points; AUC=0.729) and Ki-67 
(B, threshold=20.5%; AUC=0.727) compared to mitotic count (C, threshold=15 mitoses/50 HPF; 
AUC=0.673) and Weiss Score (D, threshold=7; AUC=0.624).  
 
Fig. 4 Classification of oncocytic (A) and myxoid cases (B) according to Weiss Score, Helsinki 
Score and Lin-Weiss-Bisceglia System (only for oncocytic tumors). Green, not evidence of disease; 
yellow, alive with disease; red, dead of disease; UMP, uncertain malignant potential. 
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Table 1 Descriptive clinicopathological features of the whole series of 225 ACC 
Parameter  
F/M ratio 131:94 (1.40) 
Mean age, y (range) 46 (1-79) 
Functional status  
Not functioning 114 
Functioning 94 
Not known 17 
Mean size, cm (range) 11.3 (2-38) 
Mean weight, g (range) 429 (8-3100) 
ACC variant  
Classical 170 
Myxoid 17 
Oncocytic (pure/mixed) 38 (24/14) 
ENSAT stage  
I 15 
II 71 
III 62 
IV 41 
Not known 36 
Disease status   
NED 76 
AWD 60 
DOD 89 
Median overall survival, mo (range) 36 (1-246) 
Abbreviations: ACC, adrenocortical carcinoma; M, male; F, female; FU, follow up; NED, no 
evidence of disease; AWD, alive with disease; DOD, died of disease. 
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Table 2 Reciprocal correlations among proliferation indices and scoring systems 
 
Parameter Mitotic count Helsinki score Weiss score 
Helsinki Score r = 0.667 
P < .0001 
− − 
Weiss Score r = 0.624 
P < .0001 
r = 0.513 
P < .0001 
− 
Weiss Score 
revised 
r = 0.642 
P < .0001 
r = 0.573 
P < .0001 
r = 0.782 
P < .0001 
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Table 3 Univariate and multivariate Cox regression analyses of overall survival 
 
Variable Univariate analysis P 
HR  95% CI 
Sex (F vs M) 0.89  0.58-1.38 .61 
Age
 
1.01 0.99-1.02 .435 
Hormonal secretion
a
 1.63 1.06-2.56 .023 
Size 1.05 1.01-1.10 .031 
Weight
 
1.00 1.00-1.01 .067 
ENSAT stage     
I vs II 3.26 0.77-13.79 .107 
I vs III 3.79 0.90-15.87 .068 
I vs IV 7.48 1.78-31.43 .005 
Presence of necrosis
b
 3.61 1.57-8.30 .001 
Mitotic count
 
1.02 1.01-1.02 <.0001 
Ki-67
 
1.02 1.01-1.03 <.0001 
ACC variant     
Conventional vs myxoid 0.96 0.45-2.39 .924 
Conventional vs oncocytic 6.57 0.04-0.63 .009 
Weiss Score
 c
 1.50 1.29-1.74 <.0001 
Weiss Score Revised
 
1.52 1.29-1.79 <.0001 
Helsinki Score 
c
 1.05 1.02-1.03 <.0001 
NOTE. The HR is for each additional year of age, cm of size, g of weight, mitosis, percentage point 
of Ki-67, unit of Weiss Score, Weiss Score Revised and Helsinki Score. 
Abbreviations: HR, hazard ratio; CI, confidence interval. 
a
 Nonsecreting ACC was the reference category. 
b
 Absence of necrosis was the reference category. 
c
 Parameters significant at multivariate survival analysis: Helsinki Score, HR 1.019 (95% CI 1.010-
1.028), P < .0001; Weiss Score, HR 1.332 (95% CI 1.132-1.566), P = .0005. 
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Figure 1 
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Figure 2 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 18 
 
Figure 3 
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Figure 4 
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Validation of the prognostic role of the “Helsinki score” in 225 cases of adrenocortical carcinoma  
 
Eleonora Duregon, Rocco Cappellesso, Valeria Maffeis, Barbara Zaggia, Laura Ventura, Alfredo 
Berruti, Massimo Terzolo, Ambrogio Fassina, Marco Volante, Mauro Papotti  
 
 The “Helsinki score” is based on morphological (mitoses and necrosis) and IHC (Ki-67) 
parameters.  
 This study validated the prognostic value of Helsinki score for adrenocortical carcinoma.  
 Helsinki Score and Weiss Score were predictors of poor prognosis on multivariate analysis.  
 Helsinki Score and Ki-67 showed best and equivalent AUC predicting disease-related 
deaths. 
 The Helsinki Score outperforms current prognostic parameters in adrenocortical carcinoma. 
